Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 11, 2023 08:00 ET | Cingulate Inc.
KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023 08:00 ET | Cingulate Inc.
KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
June 14, 2023 15:45 ET | Cingulate Inc.
KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023 07:00 ET | Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...
22157.jpg
Global Drug Delivery Partnering Deal Terms and Agreements Analysis Report 2023: Review Drug Delivery Deal Trends, Key Players, & Top Deal Values for Deals Signed Since 2016
June 06, 2023 03:13 ET | Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2016-2023" report has been added to ResearchAndMarkets.com's offering.The Global Drug delivery...
Cingulate_Logo_400x400_twitter.jpg
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023 15:45 ET | Cingulate Inc.
KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023 06:45 ET | Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 23, 2023 16:30 ET | Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
22157.jpg
Long-Acting Drug Delivery Technologies and Services Global Market Report 2023: Continued Shift from Conventional Drug Delivery Strategies Boosts Growth
January 31, 2023 07:58 ET | Research and Markets
Dublin, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The "Long-Acting Drug Delivery Technologies and Services Market - Distribution by Principle, Strategy, Compatible Dosage Form, Type of Molecule Delivered,...
22157.jpg
Non-Viral / Intracellular Drug Delivery Systems Global Market Report 2022: Demand for Systems That Can Efficiently Deliver Therapeutic Interventions in Intracellular Spaces Bolsters Growth
January 13, 2023 07:28 ET | Research and Markets
Dublin, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The "Non-Viral / Intracellular Drug Delivery Systems Market by Type of Molecule, Type of Biologics Delivered, Type of Vehicle Used, Type of Therapeutic...